Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis Market Report 2026

The antineutrophil cytoplasmic antibody (anca) associated vasculitis market size has grown strongly in recent years. It will grow from $0.63 billion in 2025 to $0.68 billion in 2026 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to improvements in autoimmune disease diagnostics, increased use of corticosteroids and immunosuppressants, expansion of nephrology and rheumatology care services, growing clinical awareness of rare vasculitis disorders, availability of standardized treatment protocols.

The antineutrophil cytoplasmic antibody (anca) associated vasculitis market size is expected to see strong growth in the next few years. It will grow to $0.95 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to increasing development of targeted biologics, rising investments in rare disease research, expansion of personalized treatment approaches, growing focus on relapse prevention strategies, increasing patient access to specialized care centers. Major trends in the forecast period include increasing adoption of biologic therapies, rising focus on early and accurate diagnosis, growing use of targeted immunosuppressive treatments, expansion of multidisciplinary disease management approaches, enhanced emphasis on long-term disease monitoring.

The increasing incidence of autoimmune diseases is anticipated to drive the growth of the ANCA-associated vasculitis market in the coming years. Autoimmune diseases occur when the immune system mistakenly attacks the body's healthy cells and tissues, perceiving them as foreign invaders such as bacteria or viruses. The rising prevalence of autoimmune diseases is attributed to environmental triggers and lifestyle factors, with greater exposure to infections and pollutants playing a significant role by disrupting immune tolerance and triggering abnormal immune responses. ANCA-associated vasculitis contributes positively to advancing autoimmune disease research and treatment by promoting the development of targeted immunosuppressive therapies, enhancing early diagnostic capabilities, and improving overall disease management strategies, ultimately leading to better patient outcomes and a deeper understanding of immune system regulation. For example, in September 2023, according to the Impact of IBD Report 2023 published by the Inflammatory Bowel Disease (IBD) Clinical and Research Centre, a Canada-based organization focused on improving the lives of patients with Crohn's disease and ulcerative colitis, the prevalence of inflammatory bowel disease (IBD), an autoimmune condition, in Canada was 825 per 100,000 people, affecting over 320,000 individuals. With an expected annual increase of 2.44% in prevalence, it is projected that by 2035, approximately 470,000 Canadians, representing 1.1% of the population, will be living with IBD. Consequently, the rising incidence of autoimmune diseases is expected to drive the ANCA-associated vasculitis market.

Major companies operating in the ANCA-associated vasculitis market are concentrating on developing innovative solutions, such as targeted therapies, to offer new treatment options for patients with this rare and serious disease. Targeted therapy for ANCA-associated vasculitis uses specialized biologic agents to selectively inhibit components of the immune system responsible for inflammation and vascular damage, thereby slowing disease progression and minimizing treatment-related toxicity. For example, in February 2023, Vifor Fresenius Medical Care Renal Pharma (VFMCRP), a Switzerland-based pharmaceutical company, announced the approval of Tavneos (avacopan) by the Therapeutic Goods Administration (TGA), an Australia-based government regulatory body, for the treatment of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), in combination with rituximab or a cyclophosphamide-based regimen. This approval represents a significant advancement as Tavneos is the first targeted therapy specifically developed for granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), the two main forms of ANCA-associated vasculitis. By selectively blocking the complement C5a receptor (C5aR1), the therapy helps manage inflammation and disease progression while reducing dependence on high-dose glucocorticoids (steroids), which are associated with severe long-term side effects.

In March 2024, Q32 Bio Inc., a US-based clinical-stage biotechnology company, merged with Homology Medicines, Inc. for an undisclosed amount. Through this merger, Q32 Bio aims to enhance its position as a public biotech company by obtaining funding to advance key biologic therapies, including bempikibart for autoimmune diseases such as atopic dermatitis and alopecia areata, and ADX-097 for complement-mediated disorders, with a Phase 2 trial in ANCA-associated vasculitis scheduled for early 2025. Homology Medicines, Inc. is a US-based clinical-stage genetic medicines company specializing in rare diseases.

Major companies operating in the antineutrophil cytoplasmic antibody (anca) associated vasculitis market are ChemoCentryx Inc, Amgen Inc, AstraZeneca Plc, GlaxoSmithKline plc, Novartis AG, Bristol‑Myers Squibb Company, Travere Therapeutics Inc, F. Hoffmann‑La Roche AG, Pfizer Inc, Sanofi SA, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, AbbVie Inc, UCB S.A., Bayer AG, Janssen Pharmaceuticals NV, Sobi AB, Alentis Therapeutics AG, InflaRx NV, NS Pharma Inc, Staidson Biopharmaceuticals Co Ltd, Genentech Inc, Regeneron Pharmaceuticals Inc, Mylan NV, Teva Pharmaceutical Industries Ltd, Biogen Inc, CSL Limited, Moderna Inc, Vertex Pharmaceuticals Inc.

North America was the largest region in the antineutrophil cytoplasmic antibody (ANCA) associated vasculitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antineutrophil cytoplasmic antibody (anca) associated vasculitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antineutrophil cytoplasmic antibody (anca) associated vasculitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the anca-associated vasculitis market by increasing costs of imported biologic drugs, immunosuppressive agents, diagnostic reagents, and advanced laboratory testing equipment. Healthcare systems in North America and Europe are most affected due to reliance on imported specialty medicines, while Asia-Pacific faces higher costs for biologic drug manufacturing inputs. These tariffs are contributing to higher treatment costs and reimbursement pressures. However, they are also encouraging regional biologics manufacturing, domestic diagnostic development, and localized supply chains for rare disease therapies.

The antineutrophil cytoplasmic antibody (anca) associated vasculitis market research report is one of a series of new reports that provides antineutrophil cytoplasmic antibody (anca) associated vasculitis market statistics, including antineutrophil cytoplasmic antibody (anca) associated vasculitis industry global market size, regional shares, competitors with a antineutrophil cytoplasmic antibody (anca) associated vasculitis market share, detailed antineutrophil cytoplasmic antibody (anca) associated vasculitis market segments, market trends and opportunities, and any further data you may need to thrive in the antineutrophil cytoplasmic antibody (anca) associated vasculitis industry. This antineutrophil cytoplasmic antibody (anca) associated vasculitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a rare autoimmune disorder marked by inflammation and injury to small and medium-sized blood vessels, predominantly impacting organs such as the kidneys, lungs, and respiratory tract, and can result in serious complications if untreated. This condition is strongly associated with nephrology, pulmonology, and rheumatology, necessitating multidisciplinary management that includes immunosuppressive therapies, corticosteroids, and advanced treatment approaches to prevent organ failure and enhance long-term patient outcomes.

The main types of antineutrophil cytoplasmic antibody (ANCA) associated vasculitis include granulomatosis with polyangiitis (GPA or Wegener's), microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA or Churg-Strauss), among others. Granulomatosis with polyangiitis (GPA), previously referred to as Wegener’s granulomatosis, is a rare, systemic, ANCA-associated vasculitis (AAV) marked by inflammation of small to medium-sized blood vessels, resulting in granuloma formation and damage predominantly affecting the respiratory tract, kidneys, and other organs. Management involves various treatments such as immunosuppressants, corticosteroids, biologics, and others, supported by diagnostic methods including blood tests, biopsy, imaging, and more.

The antineutrophil cytoplasmic antibody (ANCA) associated vasculitis market consists of revenues earned by entities by providing services such as diagnostic testing, disease management, and patient counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The antineutrophil cytoplasmic antibody (ANCA) associated vasculitis market also includes sales of biologic therapies, plasma exchange equipment, diagnostic test kits, targeted oral therapies, and monoclonal antibodies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.